Help your patients with Parkinson’s disease (PD)
Get back on
with

KYNMOBI®

KYNMOBI Power On Logo
(apomorphine HCl)
sublingual film
The first and only sublingual treatment for OFF episodes1,2

INDICATION
KYNMOBI® (apomorphine hydrochloride) sublingual film is a non-ergoline dopamine agonist indicated for the acute, intermittent treatment of "off" episodes in patients with Parkinson’s disease.

KYNMOBI sublingual film is a blue to green rectangular film with a white printed number identifying the strength (e.g., “10” is 10 mg).
KYNMOBI sublingual film is a blue to green rectangular film with a white printed number identifying the strength (e.g., “10” is 10 mg).
Request a Rep Icon

Request a Rep

 

References: 1. Kynmobi. Prescribing information. Sunovion Pharmaceuticals Inc; May 2020. 2. Olanow CW, Factor SA, Espay AJ, et al; for the CTH-300 Study Investigators. Apomorphine sublingual film for off episodes in Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 2020;19[2]:135-144.

Top

Thank you for registering with KYNMOBI!

We look forward to telling you more about KYNMOBI, a new medication to treat OFF episodes associated with Parkinson's disease, as it becomes available.

You have been successfully unsubscribed.

Please allow 7-10 days to process your request.